<DOC>
	<DOCNO>NCT00262600</DOCNO>
	<brief_summary>The primary objective trial demonstrate efficacy safety dabigatran etexilate patient non-valvular atrial fibrillation prevention stroke systemic embolism .</brief_summary>
	<brief_title>Randomized Evaluation Long Term Anticoagulant Therapy ( RE-LY ) With Dabigatran Etexilate</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criterion Patients nonvalvular atrial fibrillation ( AF ) , moderate high risk stroke , systemic embolism least one additional risk factor ( i.e . previous ischemic stroke , TIA , systemic embolism , leave ventricular dysfunction , age &gt; =75 year , age &gt; =65 either diabetes mellitus , history coronary artery disease hypertension ) Exclusion criterion 1 . Prosthetic heart valve require anticoagulation per se , hemodynamically relevant valve disease expect require surgical intervention course study 2 . Severe , disable stroke within previous 6 month , stroke within previous 14 day 3 . Conditions associate increase risk bleed 4 . Contraindication warfarin treatment 5 . Reversible cause atrial fibrillation ( e.g. , cardiac surgery , pulmonary embolism , untreated hyperthyroidism ) . 6 . Plan perform pulmonary vein ablation surgery cure AF 7 . Severe renal impairment ( estimate creatinine clearance &lt; =30 mL/min ) 8 . Active infective endocarditis 9 . Active liver disease 10 . Women pregnant , lactating , childbearing potential refuse use medically acceptable form contraception throughout study 11 . Anaemia ( haemoglobin &lt; 100g/L ) thrombocytopenia ( platelet count &lt; 100 x 109/L ) 12 . Patients develop transaminase elevation upon exposure ximelagatran 13 . Patients receive investigational drug past 30 day participate another drug study 14 . Patients consider unreliable investigator concern requirement followup study and/or compliance study drug administration , life expectancy less expected duration trial due concomitant disease , condition opinion investigator , would allow safe participation study ( e.g. , drug addiction , alcohol abuse ) 15 . Any known hypersensitivity galactose warfarin use contains galactose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>